Psychiatric inpatient cost of care before and after admission at a residential subacute step-up/step-down mental health facility.

Abstract:

BACKGROUND:Residential step-up/step-down services provide transitional care and reintegration into the community for individuals experiencing episodes of subacute mental illness. This study aims to examine psychiatric inpatient admissions, length of stay, and per capita cost of care following the establishment of a step-up/step-down Prevention And Recovery Care (PARC) facility in regional Australia. METHODS:This was a pragmatic before and after study set within a participatory action research methodology. The target sample comprised patients at a PARC facility over 15 months. Six-month individual level data prior to study entry, during, and over 6-months from study exit were examined using patient activity records. Costs were expressed in 2015-2016AU$. RESULTS:An audit included 192 people experiencing 243 episodes of care represented by males (58%), mean age = 39.3 years (SD = 12.7), primarily diagnosed with schizophrenia (48%) or mood disorders (30%). The cost of 1 day in a psychiatric inpatient unit was found to be comparable to an average of 5 treatment days in PARC; the mean cost difference per-bed day (AU$1,167) was associated with fewer and shorter inpatient stays. Reduced use of inpatient facility translated into an opportunity cost of improved patient flow equivalent to AU$12,555 per resident (bootstrapped 95% CI = $5,680-$19,280). More noticeable outcomes were observed among those who stayed in PARC for longer during index admission (rs = 0.16, p = 0.024), who have had more and lengthy inpatient stays (rs = 0.52, p < 0.001 and rs = 0.69, p < 0.001), and those who stepped-down from the hospital (p < 0.001). This information could be proactively used within step-up/step-down services to target care to patients most likely to benefit. Despite early evidence of positive association, the results warrant further investigation using an experimental study design with alongside economic evaluation. CONCLUSION:Efforts should be directed toward the adoption of cost-effective alternatives to psychiatric inpatient facilities that provide comparable or improved patient outcomes.

journal_name

J Med Econ

authors

Kinchin I,Russell AMT,Tsey K,Jago J,Wintzloff T,Meurk C,Doran CM

doi

10.1080/13696998.2019.1588126

subject

Has Abstract

pub_date

2019-05-01 00:00:00

pages

491-498

issue

5

eissn

1369-6998

issn

1941-837X

journal_volume

22

pub_type

杂志文章
  • Cost-effectiveness of sequential urate lowering therapies for the management of gout in Singapore.

    abstract::Aims: Allopurinol is the most common urate lowering therapy (ULT) used to treat gout but may cause life-threatening severe cutaneous adverse reactions (SCAR) in a small number of patients. Risk of SCAR is increased for patients with the HLA-B*58:01 genotype. When alternative ULT is required, febuxostat or probenecid a...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.1080/13696998.2020.1757456

    authors: Pruis SL,Jeon YK,Pearce F,Thong BY,Aziz MIA

    更新日期:2020-08-01 00:00:00

  • Economic analysis of ceftaroline fosamil for treating community-acquired pneumonia in Spain.

    abstract::Background: Adults admitted to hospital with community-acquired pneumonia (CAP) impose significant burden upon limited hospital resources. To achieve early response and possibly early discharge, thus reducing hospital expenditure, the choice of initial antibiotic therapy is pivotal.Methods: A cost-consequences model w...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.1080/13696998.2019.1688819

    authors: Torres A,Bassetti M,Welte T,Rivolo S,Remak E,Peral C,Charbonneau C,Hammond J,Ansari W,Grau S

    更新日期:2020-02-01 00:00:00

  • Chronic noncancer pain intensity is inversely related to analgesic adherence in pain clinics.

    abstract:OBJECTIVE:The relationship between chronic noncancer pain (CNCP) control and pain medication (analgesic) adherence has not been widely documented. The primary aim of this study was to evaluate the relationship between pain intensity and the degree of adherence to analgesic medication prescribed in pain clinics. There w...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696998.2011.598202

    authors: Stern A,Sánchez-Magro I,Rull M

    更新日期:2011-01-01 00:00:00

  • The economic value of reducing medication dosing frequency with drug delivery technologies: an evidence assessment.

    abstract:OBJECTIVE:To critically evaluate published cost-effectiveness studies of novel drug products requiring less-frequent medication dosing compared to conventional formulations of the same drug substance. METHODS:A search was conducted in the Medline and Embase databases for cost-effectiveness studies published before May...

    journal_title:Journal of medical economics

    pub_type: 杂志文章,评审

    doi:10.3111/13696991003757500

    authors: Cheng MM,Alfonso R,Best JH,Garrison LP,Bruhn D,Veenstra DL

    更新日期:2010-01-01 00:00:00

  • Long-term health-related burden of adult congenital heart diseases in Hong Kong.

    abstract::Aims: This study aimed to examine the long-term clinical and economic burden of adults with congenital heart disease (ACHD) in Hong Kong. Methods: It retrospectively analyzed 336 consecutive ACHD patients who attended the Adult Congenital Heart Clinic between January 1, 2009 and December 31, 2014. Direct medical costs...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.1080/13696998.2019.1613239

    authors: Lee VWY,Yan BP,Fong TMC,Fung AKP,Cheng FWT

    更新日期:2019-08-01 00:00:00

  • Evaluating the cost-effectiveness of percutaneous closure of a patent foramen ovale versus medical management in patients with a cryptogenic stroke: from the UK payer perspective.

    abstract:AIMS:Percutaneous closure of a patent foramen ovale (PFO) is known to lower the risk of recurrent stroke in patients with a cryptogenic stroke. However, the economic implications of transcatheter PFO closure are less well known. From a UK payer perspective, a detailed economic appraisal of PFO closure was performed for...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.1080/13696998.2018.1548355

    authors: Hildick-Smith D,Turner M,Shaw L,Nakum M,Hartaigh BÓ,Evans RM,Rhodes JF,Sondergaard L,Kasner SE

    更新日期:2019-02-01 00:00:00

  • A cost-effectiveness analysis comparing the originator follitropin alfa to its biosimilars in patients undergoing a medically assisted reproduction program from a French perspective.

    abstract:OBJECTIVE:To assess the cost-effectiveness (CE) of the originator follitropin-α (Gonal-F) in patients undergoing a medically assisted reproduction (MAR) program in comparison to its biosimilars Bemfola and Ovaleap in a French context. METHODS:A CE model was developed for France with a National Health Service (NHS) per...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.1080/13696998.2018.1551226

    authors: Grynberg M,Murphy C,Doré C,Fresneau L,Paillet S,Petrica N,Frédérique M,Ravonimbola H

    更新日期:2018-11-21 00:00:00

  • Satisfaction with botulinum toxin treatment in post-stroke spasticity: results from two cross-sectional surveys (patients and physicians).

    abstract:OBJECTIVE:To characterize patient and physician satisfaction with current standard-of-care botulinum toxin treatment regimens for symptom control in patients with post-stroke spasticity using structured interviews with patients and physicians. RESEARCH DESIGN AND METHODS:Two cross-sectional surveys were conducted in C...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696998.2014.925462

    authors: Bensmail D,Hanschmann A,Wissel J

    更新日期:2014-09-01 00:00:00

  • Cost effectiveness of transcatheter aortic valve replacement compared to medical management in inoperable patients with severe aortic stenosis: Canadian analysis based on the PARTNER Trial Cohort B findings.

    abstract:OBJECTIVE:The only effective treatment for severe aortic stenosis (AS) is valve replacement. However, many patients with co-existing conditions are ineligible for surgical valve replacement, historically leaving medical management (MM) as the only option which has a poor prognosis. Transcatheter Aortic Valve Replacemen...

    journal_title:Journal of medical economics

    pub_type: 杂志文章,随机对照试验

    doi:10.3111/13696998.2013.770747

    authors: Hancock-Howard RL,Feindel CM,Rodes-Cabau J,Webb JG,Thompson AK,Banz K

    更新日期:2013-01-01 00:00:00

  • Direct medical costs for patients with tuberous sclerosis complex and surgical resection of subependymal giant cell astrocytoma: a US national cohort study.

    abstract:OBJECTIVE:To estimate direct medical costs for patients with tuberous sclerosis complex (TSC) and surgical resection of subependymal giant-cell astrocytoma (SEGA). METHODS:This retrospective cohort study selected patients who had SEGA surgery and TSC claims between 2000-2011 from three large US nationwide claims datab...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696998.2014.1001513

    authors: Sun P,Liu Z,Krueger D,Kohrman M

    更新日期:2015-05-01 00:00:00

  • Descriptive analysis of Medicaid patients with postherpetic neuralgia treated with lidocaine patch 5%.

    abstract:OBJECTIVES:To compare demographic and comorbidity profiles and healthcare costs of Medicaid patients with postherpetic neuralgia (PHN) treated with lidocaine patch 5% (lidocaine patch) versus patients not treated with the lidocaine patch. Repeat comparison for the subset of patients treated in long-term care (LTC) sett...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696998.2010.499819

    authors: Kirson NY,Ivanova JI,Birnbaum HG,Wei R,Kantor E,Amy Puenpatom R,Ben-Joseph RH,Summers KH

    更新日期:2010-01-01 00:00:00

  • Fall-related healthcare use and costs in neurogenic orthostatic hypotension with Parkinson's disease.

    abstract:AIMS:To compare patient characteristics, rates, and costs of medically attended falls among patients with Parkinson's disease (PD) and probable PD plus neurogenic orthostatic hypotension (PD + nOH). MATERIALS AND METHODS:MarketScan Commercial and Medicare Supplemental databases (January 1, 2009-December 31, 2013) were...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.1080/13696998.2017.1284668

    authors: François C,Biaggioni I,Shibao C,Ogbonnaya A,Shih HC,Farrelly E,Ziemann A,Duhig A

    更新日期:2017-05-01 00:00:00

  • Epidemiology, management, and economic impact of acute myeloid leukemia and myelodysplastic syndrome in Spain at the hospital level: a claims database analysis.

    abstract:OBJECTIVES:This study reviewed patient characteristics, management, and medical costs of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDSs) in Spanish hospitals. METHODS:Data were extracted from the Spanish Ministry of Health records via a claims database containing patient records from 192 private and ...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.1080/13696998.2020.1840180

    authors: Marsà A,Ascanio M,Diaz-García J,Darbà J

    更新日期:2020-11-02 00:00:00

  • The economic burden of chronic obstructive pulmonary disease from 2004 to 2013.

    abstract:OBJECTIVES:This study examines the epidemiology and economic impact of chronic obstructive pulmonary disease (COPD) at a nationwide level in South Korea. METHODS:This retrospective analysis used the societal cost-of-illness framework, consisting of direct medical costs, direct non-medical costs, and indirect costs. In...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696998.2015.1100114

    authors: Kim J,Lee TJ,Kim S,Lee E

    更新日期:2016-01-01 00:00:00

  • The effects of global budget on cost control and readmission in rural China: a difference-in-difference analysis.

    abstract:BACKGROUND:Global budget (GB) is considered one of the most important payment methods available. Since a new round of healthcare system reforms in 2009, the Chinese government has been paying attention to this prospective payment. However, it is unclear whether GB has influenced cost control and how it works in rural C...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.1080/13696998.2017.1336448

    authors: He R,Miao Y,Ye T,Zhang Y,Tang W,Li Z,Zhang L

    更新日期:2017-09-01 00:00:00

  • Cost effectiveness of palivizumab in children with congenital heart disease in Germany.

    abstract:OBJECTIVES:To assess the cost effectiveness of palivizumab, a humanised monoclonal antibody, used as prevention against severe respiratory syncytial virus (RSV) infection requiring hospitalisation, in infants with haemodynamically significant congenital heart disease (CHD) in the German healthcare setting. STUDY DESIG...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696990903347172

    authors: Nuijten M,Lebmeier M,Wittenberg W

    更新日期:2009-01-01 00:00:00

  • Treatment patterns and healthcare system burden of managed care patients with suspected pulmonary arterial hypertension in the United States.

    abstract:OBJECTIVES:To describe treatment patterns and healthcare burden among individuals with suspected pulmonary arterial hypertension (PAH), as identified through a practice guideline-based healthcare claims algorithm. METHODS:Adults with evidence of PAH from 1 January 2004 (commercial and Medicaid) or 1 July 2006 (Medicar...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696998.2012.690801

    authors: Copher R,Cerulli A,Watkins A,Laura Monsalvo M

    更新日期:2012-01-01 00:00:00

  • Adult height and health-related quality of life after growth hormone therapy in small for gestational age subjects.

    abstract:OBJECTIVE:To estimate health-related quality of life (HRQoL) in non-growth hormone deficient (GHD) small for gestational age (SGA) children before and after growth hormone (GH) treatment to adult height (AH). METHODS:This was a multicentre, two-arm trial. Following an initial 2-year double-blind study period, patients...

    journal_title:Journal of medical economics

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.3111/13696998.2010.484323

    authors: Bannink E,Djurhuus CB,Christensen T,Jøns K,Hokken-Koelega A

    更新日期:2010-01-01 00:00:00

  • The cost-effectiveness of somatropin treatment for short children born small for gestational age (SGA) and children with growth hormone deficiency (GHD) in Sweden.

    abstract:OBJECTIVE:Reduction in health-related quality of life is common in children born small for gestational age (SGA) or children with growth hormone deficiency (GHD). Growth hormone treatment with somatropin in these children leads to normalisation of height. The aim of this study was to determine whether somatropin is a c...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696991003652248

    authors: Christensen T,Fidler C,Bentley A,Djurhuus C

    更新日期:2010-03-01 00:00:00

  • Healthcare resource utilization and costs associated with patients prescribed afatinib or erlotinib as first-line therapy for EGFR mutation-positive NSCLC in the United States.

    abstract::Aims: To assess healthcare resource utilization (HCRU) and costs in patients with non-small cell lung cancer treated with the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors afatinib or erlotinib as first-line treatment.Materials and methods: This retrospective analysis used data from three large ad...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.1080/13696998.2019.1645681

    authors: Samuelsen C,Lim J,Golembesky A,Shrestha S,Wang L,Griebsch I

    更新日期:2020-01-01 00:00:00

  • Persistence, adherence, and all-cause healthcare costs in atazanavir- and darunavir-treated patients with human immunodeficiency virus in a real-world setting.

    abstract:OBJECTIVES:Atazanavir (ATV) and darunavir (DRV) are protease inhibitors approved for HIV treatment in combination with ritonavir (/r). The objectives of this study were to compare persistence (time to treatment discontinuation/modification), adherence, and healthcare costs among patients with human immunodeficiency vir...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696998.2015.1128942

    authors: Farr AM,Johnston SS,Ritchings C,Brouillette M,Rosenblatt L

    更新日期:2016-01-01 00:00:00

  • Budget impact analysis of secukinumab versus adalimumab in the treatment of ankylosing spondylitis.

    abstract:BACKGROUND:Biologic treatments have enhanced the treatment outcomes of patients with active ankylosing spondylitis (AS). Until recently, TNF-alpha-inhibitors have been the only biologics approved for the treatment of active AS. The objective of this study was to assess the potential financial impact of the first non-TN...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.1080/13696998.2018.1551227

    authors: Purmonen T,Törmälehto S,Wahlman H,Puolakka K

    更新日期:2019-02-01 00:00:00

  • Effects of innovation and insurance coverage on price elasticity of demand for prescription drugs: some empirical lessons in pharmacoeconomics.

    abstract:AIM:Prescription drug prices in the United States are considered rather extreme. Americans spend over $460 billion on drugs annually, or almost 17 percent of total national healthcare spending. How innovation incentives and insurance coverage drive pricing, diffusion, and utilization of drugs, under conditions of risk ...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.1080/13696998.2020.1772797

    authors: Mendoza RL

    更新日期:2020-09-01 00:00:00

  • Health economic evaluation of insulin glargine vs NPH insulin in intensified conventional therapy for type 1 diabetes in Germany.

    abstract:OBJECTIVE:Basal insulin analogs are well established in the treatment of type 1 diabetes in Germany. However, little is known about their economic impact. The aim of this study for an adult population was to compare, from the perspective of the Statutory Health Insurance (SHI), the cost effectiveness of the long-acting...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696998.2012.713879

    authors: Pfohl M,Schädlich PK,Dippel FW,Koltermann KC

    更新日期:2012-01-01 00:00:00

  • Assessing the economic impact of Rx-to-OTC switches: systematic review and guidelines for future development.

    abstract:INTRODUCTION:Switching drugs from prescription to non-prescription status (Rx-to-OTC) presents a unique set of challenges and opportunities to policy-makers and the industry in terms of managing health outcomes, pharmaceutical spending, and steering of consumer choices of therapy. Decision-analytic models are used to a...

    journal_title:Journal of medical economics

    pub_type: 杂志文章,评审

    doi:10.3111/13696998.2013.793693

    authors: Cohen J,Millier A,Karray S,Toumi M

    更新日期:2013-01-01 00:00:00

  • Cost analysis of plasma-derived factor VIII/von Willebrand factor versus recombinant factor VIII for treatment of previously untreated patients with severe hemophilia A in the United States.

    abstract:BACKGROUND:Inhibitor development to factor VIII (FVIII) hemophilia therapy results in increased complications and substantial economic costs. The SIPPET study, the first randomized controlled trial to compare the immunogenicity of plasma-derived FVIII (pdFVIII)/von Willebrand factor (VWF) and recombinant-DNA-derived FV...

    journal_title:Journal of medical economics

    pub_type: 杂志文章,随机对照试验

    doi:10.1080/13696998.2018.1468335

    authors: Neufeld EJ,Sidonio RF Jr,O'Day K,Runken MC,Meyer K,Spears J

    更新日期:2018-08-01 00:00:00

  • Risk and cost of infection-related hospitalizations in medicare beneficiaries with comorbid rheumatoid arthritis treated with abatacept versus other targeted disease-modifying anti-rheumatic drugs.

    abstract:OBJECTIVE:This study evaluated infection-related hospitalization risk and cost in tumor necrosis factor inhibitor (TNFi)-experienced and targeted DMARD (tDMARD) naïve rheumatoid arthritis (RA) patients that were treated with abatacept, TNFi, or other non-TNFi. METHODS:This retrospective study used 100% Medicare Fee-fo...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.1080/13696998.2021.1881525

    authors: Patel V,Pulungan Z,Shah A,Kambhampati M,Lobo F,Petrilla A

    更新日期:2021-01-27 00:00:00

  • Comparison of historical medical spending patterns among the BRICS and G7.

    abstract:OBJECTIVE:The past few decades have been marked by a bold increase in national health spending across the globe. Rather successful health reforms in leading emerging markets such as BRICS reveal a reshaping of their medical care-related expenditures. There is a scarcity of evidence explaining differences in long-term m...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696998.2015.1093493

    authors: Jakovljevic MM

    更新日期:2016-01-01 00:00:00

  • Cost-effectiveness analysis of solifenacin versus oxybutynin immediate-release in the treatment of patients with overactive bladder in the United Kingdom.

    abstract:OBJECTIVE:To carry out a cost-utility analysis comparing initial treatment with solifenacin 5 mg/day vs oxybutynin immediate-release (IR) 15 mg/day for the treatment of patients with overactive bladder (OAB) from the perspective of the U.K. National Health Service (NHS). METHODS:A Markov model with six health states w...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696998.2013.829079

    authors: Hart WM,Abrams P,Munro V,Retsa P,Nazir J

    更新日期:2013-10-01 00:00:00

  • Updated cost-effectiveness analysis of onabotulinumtoxinA for the prevention of headache in adults with chronic migraine who have previously received three or more preventive treatments in the UK.

    abstract::Aims: OnabotulinumtoxinA is recommended by NICE for the treatment of chronic migraine. This economic evaluation provides updated estimates of the cost-effectiveness of onabotulinumtoxinA for chronic migraine using new utility estimates in an existing model structure.Methods: A previously published model was revised to...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.1080/13696998.2019.1675417

    authors: Hollier-Hann G,Curry A,Onishchenko K,Akehurst R,Ahmed F,Davies B,Keyzor I

    更新日期:2020-01-01 00:00:00